Lacibloc

Treatment of HTN either alone or in combination w/ other antihypertensives (eg, β-blockers, diuretics, & ACE inhibitors).

Initially 2 mg once daily taken at the same time each day, preferably in morning. May be increased to 4 mg & if necessary to 6 mg after allowing adequate time for full effect to occur.

May be taken with or without food: Do not take w/ grapefruit juice.

Hypersensitivity. Patients w/ severe aortic stenosis.

Caution in patients w/ poor cardiac reserve. Pregnancy & lactation. 4 mg: Caution in patients w/ unstable angina pectoris; after recent MI; w/ impaired liver function. Insufficient data available for patients w/ severe hepatic impairment. No experience in childn. 6 mg: Should not be used to treat angina attack in chronic stable angina. May increase risk of developing heart failure in patients w/ severe aortic stenosis. Sudden w/drawal might be associated w/ exacerbation of angina. Not to be used in cardiogenic shock, in patients who have recently suffered an MI, or in acute unstable angina. Caution in patients w/ hypotension; heart failure; pre-existing abnormalities in the activity of the SA & AV nodes; congenital or documented acquired QT prolongation. Concomitant use w/ medications known to prolong the QT interval eg, class I & III antiarrhythmics, TCAs, some antipsychotics, antibiotics (eg, erythromycin) & some antihistamines (eg, terfenadine).

Headache, dizziness; palpitation, tachycardia; flushing; nausea & other GI disturbances. 4 mg: Skin rash (including erythema & itching); polyuria; asthenia, oedema; reversible increase in alkaline phosphatase. 6 mg: Hypotension, peripheral edema, GI disturbances, increased micturition frequency, lethargy, eye pain, mental depression.

May have an additive hypotensive effect w/ other hypotensive agents including anti-hypertensives (eg, diuretics, β-blockers, or ACE inhibitors). Altered bioavailability w/ grapefruit juice. Reversed decrease in renal plasma flow & GFR induced by cyclosporin in patients w/ renal transplant. 4 mg: Increased plasma level by simultaneous administration of cimetidine. Significant inhibitors & inducers of CYP3A4 administered concurrently may interact w/ the metabolism & elimination of lacidipine. 6 mg: Enhanced antihypertensive effects w/ drugs eg, aldesleukin & antipsychotics that cause hypotension. May modify insulin & glucose responses. Interactions may occur w/ other drugs sharing the same metabolic pathway (eg, quinidine), & w/ enzyme inducers (eg, carbamazepine, phenytoin, & rifampicin), & enzyme inhibitors (eg, cimetidine & erythromycin).

Calcium Antagonists

C08CA09 - lacidipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.

Rx